Developer docs
API playgroundTry for free, no card

Search company profiles

Helocyte

Full company profile

uuid0003qu2

Namestring
Helocyte
Legal namestring
Helocyte, Inc.
Websiteurl
helocyte.com
Company typeenum
Private
Founded yearint
2015
Descriptiontext

Helocyte is a clinical-stage biopharmaceutical company developing novel immunotherapies for the prevention and treatment of cytomegalovirus (CMV) and related infections in immunocompromised patients. Founded in 2015 as a majority-owned subsidiary of Fortress Biotech, Inc. (NASDAQ: FBIO), Helocyte is headquartered in New York with 1-10 employees and operates as a virtual R&D organization. Its pipeline addresses CMV reactivation in allogeneic hematopoietic stem cell transplant (HSCT) recipients, solid organ transplant recipients, HIV/CMV co-infected adults, and congenital CMV, an indication with no approved vaccine.

The company's core technology is a recombinant Modified Vaccinia Ankara (MVA) viral vector vaccine platform exclusively licensed from City of Hope. The lead asset, Triplex, is a universal (non-HLA-restricted) vaccine engineered to induce durable virus-specific T cell responses against three CMV immuno-dominant proteins (pp65, IE1, IE2), and has been administered to over 150 subjects across Phase 1 and Phase 2 studies. Additional pipeline assets include PepVax (T-cell immunotherapeutic for transplant CMV control), Pentamer/ConVax (a neutralizing-antibody vaccine for congenital CMV), and an option-licensed bispecific CMV/HIV CAR T cell therapy. The technology is anchored by Don J. Diamond, Ph.D., the City of Hope scientist who originated Triplex and chairs Helocyte's Scientific Advisory Board.

Helocyte's business model is pre-commercial: it has no marketed products and generates no product revenue, instead funding clinical development through non-dilutive NIH grants (NCI, NIAID, CIRM) channeled primarily to City of Hope and University of Washington, and through Fortress Biotech subsidiary financing. Distribution to patients occurs via a network of up to 20 US transplant centers running Phase 2 trials. Future revenue, when it materializes, would derive from licensing, royalty, or partnership economics with larger pharmaceutical companies, as stated in the company's own revenue model. The company is therefore best understood as a clinical-development platform whose value inflection points are Phase 2/3 readouts and partnership transactions rather than near-term product sales.

Short descriptiontext

Helocyte is a clinical-stage biopharmaceutical subsidiary of Fortress Biotech developing recombinant MVA-based CMV immunotherapies (Triplex, PepVax, Pentamer) and a bispecific CMV/HIV CAR T cell therapy for transplant recipients, HIV-positive adults, and congenital CMV.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersNew York, United States
HQ citystring
New York
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cytomegalovirus vaccines, T-cell immunotherapies, viral vector vaccines, transplant infectious disease, clinical-stage biopharmaceuticals
Industry1 code
PRIMARYHLAAAEAD
Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Clinical-stage Biopharmaceuticals (CMV Immunotherapy)
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Vaccine Development and Commercialization
TypeLicensing Royalties
Description

As a clinical-stage biopharmaceutical company, Helocyte is developing CMV vaccines (Triplex, PepVax, ConVax) for prevention and treatment of cytomegalovirus in transplant recipients and immunocompromised patients. The company has not yet commercialized any products and does not have product revenue.

helocyte.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Helocyte is a clinical-stage biopharmaceutical company developing a pipeline of novel T-cell immunotherapies and vaccines for the prevention and treatment of cytomegalovirus (CMV) in immunocompromised patients, including allogeneic stem cell transplant recipients, solid organ transplant recipients, and HIV/CMV co-infected adults. The company uses a proprietary recombinant Modified Vaccinia Ankara (MVA) viral vector platform licensed from City of Hope to engineer vaccines such as Triplex, PepVax, and ConVax/Pentamer. Helocyte has no approved products and no product revenue; operations are funded by NIH grants and its parent company Fortress Biotech.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 18% CMV reactivation rate in recipients of Triplex-vaccinated donors vs 37% in similar cohorts prophylactically treated with letermovir (antiviral)
+3 more records
Product overview1 text field

Helocyte is a clinical-stage company developing a portfolio of novel immunotherapies for the prevention and treatment of cancer and infectious diseases, with a primary focus on cytomegalovirus (CMV). The company's core products include Triplex, a recombinant MVA viral vector vaccine targeting CMV proteins for transplant recipients; PepVax, another T-cell immunotherapy for CMV control; and ConVax/Pentamer, a vaccine for congenital CMV prevention. Additionally, Helocyte holds an option for a bispecific CMV/HIV CAR T cell therapy to be used in combination with Triplex for HIV treatment. The company operates as a majority-owned subsidiary of Fortress Biotech, with technology licensed from City of Hope.

Product and service4 records
1Triplex
CategoryCancer and Infectious Disease Immunotherapy
Description

A universal (non-HLA-restricted) recombinant Modified Vaccinia Ankara (MVA) viral vector vaccine engineered to induce a robust and durable virus-specific T cell response to three immuno-dominant CMV proteins (pp65, IE1, IE2) for controlling CMV complications in transplant recipients and HIV/CMV co-infected adults.

2PepVax
CategoryCancer and Infectious Disease Immunotherapy
Description

A T-cell immunotherapeutic vaccine for controlling CMV in allogeneic hematopoietic stem cell transplant and solid organ transplant recipients.

3ConVax (Pentamer)
CategoryCancer and Infectious Disease Immunotherapy
Description

A universal immunotherapeutic vaccine designed to induce a neutralizing antibody response to prevent the transmission of CMV from mother to fetus (congenital CMV prevention).

4CMV/HIV CAR T Cell Therapy
CategoryCancer and Infectious Disease Cell Therapy
Description

A novel bispecific Chimeric Antigen Receptor T cell therapy targeting both CMV and HIV being developed for the treatment of adults living with HIV-1.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2025-01-01
Description

Major transplant research centers in Boston participating as clinical trial sites in the Phase 2 study of Triplex vaccination in stem cell donors to reduce CMV events in HSCT recipients.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

University of Washington's Solid-Organ Transplant Infectious Disease Program is leading the COLT (CMV vaccine in Orthotopic Liver Transplant) Phase 2 clinical trial. Dr. Ajit Limaye serves as Principal Investigator. The NIAID grant ($9.0M to date, estimated additional $12M over four years) is awarded to University of Washington Seattle to support this multi-center trial across up to 20 transplant centers.

3University of California, San Diego
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2023-01-01
Description

UC San Diego is participating in the Phase 1 clinical trial of the bispecific CMV/HIV CAR T cell therapy funded by CIRM. The trial is led by Dr. Sara Gianella and Dr. Davey Smith. UCSD is also a site for the Phase 2 trial of Triplex in HIV/CMV co-infected adults.

helocyte.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2015-01-01
Description

City of Hope, a world-renowned cancer research and treatment center, developed the Triplex CMV vaccine technology and exclusively licensed it to Helocyte in 2015. Dr. Don J. Diamond, Chair of the Department of Experimental Therapeutics at City of Hope, led the development of Triplex and serves as Co-Founder and Chairman of Helocyte's Scientific Advisory Board. The partnership includes licenses to Triplex, PepVax, and option rights to Pentamer and bispecific CMV/HIV CAR T cell therapy. Helocyte could pay City of Hope in excess of $100MM in upfront, milestone and other payments if all programs are successfully developed and commercialized.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Market position
Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Helocyte

Clinical-stage Biopharmaceuticals (CMV Immunotherapy)helocyte.com

Helocyte is a clinical-stage biopharmaceutical subsidiary of Fortress Biotech developing recombinant MVA-based CMV immunotherapies (Triplex, PepVax, Pentamer) and a bispecific CMV/HIV CAR T cell therapy for transplant recipients, HIV-positive adults, and congenital CMV.

What Helocyte does

Helocyte is a clinical-stage biopharmaceutical company developing novel immunotherapies for the prevention and treatment of cytomegalovirus (CMV) and related infections in immunocompromised patients. Founded in 2015 as a majority-owned subsidiary of Fortress Biotech, Inc. (NASDAQ: FBIO), Helocyte is headquartered in New York with 1-10 employees and operates as a virtual R&D organization. Its pipeline addresses CMV reactivation in allogeneic hematopoietic stem cell transplant (HSCT) recipients, solid organ transplant recipients, HIV/CMV co-infected adults, and congenital CMV, an indication with no approved vaccine.

The company's core technology is a recombinant Modified Vaccinia Ankara (MVA) viral vector vaccine platform exclusively licensed from City of Hope. The lead asset, Triplex, is a universal (non-HLA-restricted) vaccine engineered to induce durable virus-specific T cell responses against three CMV immuno-dominant proteins (pp65, IE1, IE2), and has been administered to over 150 subjects across Phase 1 and Phase 2 studies. Additional pipeline assets include PepVax (T-cell immunotherapeutic for transplant CMV control), Pentamer/ConVax (a neutralizing-antibody vaccine for congenital CMV), and an option-licensed bispecific CMV/HIV CAR T cell therapy. The technology is anchored by Don J. Diamond, Ph.D., the City of Hope scientist who originated Triplex and chairs Helocyte's Scientific Advisory Board.

Helocyte's business model is pre-commercial: it has no marketed products and generates no product revenue, instead funding clinical development through non-dilutive NIH grants (NCI, NIAID, CIRM) channeled primarily to City of Hope and University of Washington, and through Fortress Biotech subsidiary financing. Distribution to patients occurs via a network of up to 20 US transplant centers running Phase 2 trials. Future revenue, when it materializes, would derive from licensing, royalty, or partnership economics with larger pharmaceutical companies, as stated in the company's own revenue model. The company is therefore best understood as a clinical-development platform whose value inflection points are Phase 2/3 readouts and partnership transactions rather than near-term product sales.

Helocyte firmographics

Firmographics
Name
Helocyte
Legal name
Helocyte, Inc.
Website
https://helocyte.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
1–10 employees
Short description
Helocyte is a clinical-stage biopharmaceutical subsidiary of Fortress Biotech developing recombinant MVA-based CMV immunotherapies (Triplex, PepVax, Pentamer) and a bispecific CMV/HIV CAR T cell therapy for transplant recipients, HIV-positive adults, and congenital CMV.
Ownership category
akta.pro rank

Helocyte industry classification

Industry
Product category
Clinical-stage Biopharmaceuticals (CMV Immunotherapy)
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAEAD
Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics

Keywords

  • Cytomegalovirus vaccines
  • T-cell immunotherapies
  • Viral vector vaccines
  • Transplant infectious disease
  • Clinical-stage biopharmaceuticals

Where Helocyte is headquartered

Location

Headquarters

HQ city
New York
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Helocyte business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Vaccine Development and Commercialization: As a clinical-stage biopharmaceutical company, Helocyte is developing CMV vaccines (Triplex, PepVax, ConVax) for prevention and treatment of cytomegalovirus in transplant recipients and immunocompromised patients. The company has not yet commercialized any products and does not have product revenue.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Helocyte product offering

Product offering

Core offering

Helocyte is a clinical-stage biopharmaceutical company developing a pipeline of novel T-cell immunotherapies and vaccines for the prevention and treatment of cytomegalovirus (CMV) in immunocompromised patients, including allogeneic stem cell transplant recipients, solid organ transplant recipients, and HIV/CMV co-infected adults. The company uses a proprietary recombinant Modified Vaccinia Ankara (MVA) viral vector platform licensed from City of Hope to engineer vaccines such as Triplex, PepVax, and ConVax/Pentamer. Helocyte has no approved products and no product revenue; operations are funded by NIH grants and its parent company Fortress Biotech.

Product overview

Helocyte is a clinical-stage company developing a portfolio of novel immunotherapies for the prevention and treatment of cancer and infectious diseases, with a primary focus on cytomegalovirus (CMV). The company's core products include Triplex, a recombinant MVA viral vector vaccine targeting CMV proteins for transplant recipients; PepVax, another T-cell immunotherapy for CMV control; and ConVax/Pentamer, a vaccine for congenital CMV prevention. Additionally, Helocyte holds an option for a bispecific CMV/HIV CAR T cell therapy to be used in combination with Triplex for HIV treatment. The company operates as a majority-owned subsidiary of Fortress Biotech, with technology licensed from City of Hope.

Differentiator

Problem solved

Functional benefit

Products and services

  • Triplex A universal (non-HLA-restricted) recombinant Modified Vaccinia Ankara (MVA) viral vector vaccine engineered to induce a robust and durable virus-specific T cell response to three immuno-dominant CMV proteins (pp65, IE1, IE2) for controlling CMV complications in transplant recipients and HIV/CMV co-infected adults.
  • PepVax A T-cell immunotherapeutic vaccine for controlling CMV in allogeneic hematopoietic stem cell transplant and solid organ transplant recipients.
  • ConVax (Pentamer) A universal immunotherapeutic vaccine designed to induce a neutralizing antibody response to prevent the transmission of CMV from mother to fetus (congenital CMV prevention).
  • CMV/HIV CAR T Cell Therapy A novel bispecific Chimeric Antigen Receptor T cell therapy targeting both CMV and HIV being developed for the treatment of adults living with HIV-1.

Quantifiable outcome

  • 18% CMV reactivation rate in recipients of Triplex-vaccinated donors vs 37% in similar cohorts prophylactically treated with letermovir (antiviral)
  • +3 more outcomes

Companies that use Helocyte

Customer profile

Segments4 records

Ideal customer profiles2 records

Helocyte technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Helocyte partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered major and core.

  • Brigham & Women's Hospital and Dana-Farber Cancer InstitutemajorStrategic or Co-development Partner · 1 January 2025Major transplant research centers in Boston participating as clinical trial sites in the Phase 2 study of Triplex vaccination in stem cell donors to reduce CMV events in HSCT recipients.
  • University of WashingtoncoreStrategic or Co-development Partner · 1 January 2024University of Washington's Solid-Organ Transplant Infectious Disease Program is leading the COLT (CMV vaccine in Orthotopic Liver Transplant) Phase 2 clinical trial. Dr. Ajit Limaye serves as Principal Investigator. The NIAID grant ($9.0M to date, estimated additional $12M over four years) is awarded to University of Washington Seattle to support this multi-center trial across up to 20 transplant centers.
  • University of California, San DiegomajorStrategic or Co-development Partner · 1 January 2023UC San Diego is participating in the Phase 1 clinical trial of the bispecific CMV/HIV CAR T cell therapy funded by CIRM. The trial is led by Dr. Sara Gianella and Dr. Davey Smith. UCSD is also a site for the Phase 2 trial of Triplex in HIV/CMV co-infected adults.
  • City of Hope National Medical CentercoreStrategic or Co-development Partner · 1 January 2015City of Hope, a world-renowned cancer research and treatment center, developed the Triplex CMV vaccine technology and exclusively licensed it to Helocyte in 2015. Dr. Don J. Diamond, Chair of the Department of Experimental Therapeutics at City of Hope, led the development of Triplex and serves as Co-Founder and Chairman of Helocyte's Scientific Advisory Board. The partnership includes licenses to Triplex, PepVax, and option rights to Pentamer and bispecific CMV/HIV CAR T cell therapy. Helocyte could pay City of Hope in excess of $100MM in upfront, milestone and other payments if all programs are successfully developed and commercialized.

Scale indicators9 records

Recent moves7 records

Expansion highlights5 records

Helocyte competitors and assessment

Company assessment

Market position

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

Helocyte social profiles

Digital presence

Helocyte financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Helocyte leadership team

Management profile

Number of profiles

Profiles4 records

Helocyte funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Helocyte M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Helocyte

What does Helocyte do?

Helocyte is a clinical-stage biopharmaceutical company developing a pipeline of novel T-cell immunotherapies and vaccines for the prevention and treatment of cytomegalovirus (CMV) in immunocompromised patients, including allogeneic stem cell transplant recipients, solid organ transplant recipients, and HIV/CMV co-infected adults. The company uses a proprietary recombinant Modified Vaccinia Ankara (MVA) viral vector platform licensed from City of Hope to engineer vaccines such as Triplex, PepVax, and ConVax/Pentamer. Helocyte has no approved products and no product revenue; operations are funded by NIH grants and its parent company Fortress Biotech.

Is Helocyte a public or private company?

Helocyte is a private company. It is classified as corporate owned and is currently operating.

When was Helocyte founded?

Helocyte was founded in 2015. It employs 1 to 10 people.

Where is Helocyte based?

Helocyte is headquartered in New York, United States, in the North America region.

How does Helocyte make money?

One revenue line is on record: vaccine Development and Commercialization.

Does Helocyte have an API?

No public API is recorded for Helocyte.

What industry is Helocyte in?

Helocyte's product category is Clinical-stage Biopharmaceuticals (CMV Immunotherapy). Its primary akta.pro industry code is HLAAAEAD, Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
openPR.comCytomegalovirus (CMV) Infection Pipeline Set for Strategic Expansion Through 2026 with 20+ Therapies and Robust Innovation from ModernaTX, Helocyte, VBI Vaccines, and GSK | DelveInsightDelveInsight's market research report identifies 15+ companies collectively developing 20+ therapeutic candidates for Cytomegalovirus (CMV) infection, spanning vaccines, antivirals, and immune-targeted therapies across various clinical stages. Key players including ModernaTX, Helocyte, VBI Vaccines, and GlaxoSmithKline are advancing vaccine candidates through clinical development, with mRNA-1647 and Triplex in Phase II and VBI-1501 in Phase I. The report highlights a shift toward preventive vaccine approaches driven by mRNA and viral vector technologies, aiming to address unmet needs in congenital CMV prevention and immunocompromised patient populations.GlobeNewswireHelocyte Announces $3.22 Million Grant from the NationalHelocyte announced a $3.22 million NCI grant to City of Hope for two multicenter Phase 2 trials of its CMV vaccine Triplex. The trials will evaluate safety and immunological response in stem cell donors to reduce CMV events in high-risk transplant recipients. The vaccine has been dosed safely in over 150 patients.HelocyteHelocyte Announces $3.22 Million Grant from the National Cancer Institute for Triplex Phase 2 Clinical Trial Program – HelocyteHelocyte, a subsidiary of Fortress Biotech, announced that the National Cancer Institute awarded a $3.22 million grant to City of Hope for clinical studies of Triplex, a cytomegalovirus vaccine developed by Helocyte. The funding supports two multicenter Phase 2 trials evaluating the vaccine's ability to enhance protective immunity in stem cell donors to reduce CMV risks in transplant recipients. This grant advances the development of Triplex, which is currently being tested in multiple other clinical trials for various conditions.GlobeNewswireHelocyte Announces $3.22 Million Grant from the NationalThe National Cancer Institute has awarded a $3.22 million grant to City of Hope to fund two Phase 2 clinical trials for Triplex, a cytomegalovirus vaccine developed by Helocyte. This funding will evaluate the vaccine's ability to enhance protective immunity in stem cell donors and reduce CMV risks in high-risk transplant recipients. Helocyte will provide clinical materials to support these studies, which build upon previous pilot data demonstrating safety and immunogenicity.GlobeNewswireHelocyte, Inc. Announces Positive Data from Stem Cell Transplant Donor Vaccination Trial to be Presented at the 2023 Tandem Meetings: Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTRHelocyte announced positive data from a Phase 1 pilot trial of its CMV vaccine Triplex, to be presented at the 2023 Tandem Meetings. The trial showed lower CMV events requiring antiviral intervention (18% vs 37% with letermovir) and higher CMV-specific T cells in recipients of vaccinated donors. The company plans to advance Triplex in ongoing and planned trials.